Clinical radionuclide therapy

Abstract

Clinical applications of targeted radionuclide treatment have evolved considerably over the last 10-20 years, principally as a result of an improved understanding of tumour biology, and the identification of biochemical pathways and protein targets expressed preferentially on tumours compared to normal tissue. As a result, targeted therapy of cancer with radionuclides has evolved to include a number of therapies that have achieved success in the clinic, and a broad range of strategies that are being actively pursued in laboratory studies and clinical trials. © 2008 Springer Science+Business Media B.V.